ALLERGAN, Inc. (NY:AGN)
58.28
0.47 (0.8%)
| ALLERGAN, Inc. (NY:AGN) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $58.75 | 52 Week High | $64.08 | ||
| Open | $58.80 | 52 Week Low | $35.41 | ||
| Day High | $58.89 | P/E | 32.20 | ||
| Day Low | $57.78 | EPS | $1.81 | ||
| Volume | 582,643 | ||||
| More AGN Info: Chart SEC Filings Profile Historical Options | |||||
Allergan Inc. Summary
Allergan, Inc. develops and commercializes pharmaceutical and medical device products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, and other specialty markets worldwide.
Executives
David E.I. Pyott - Chairman, CEO
Links
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| MRX | 5 | CEPH | 4 |
| FRX | 4 | MCO | 4 |
| ACL | 3 | ASIA | 3 |
| HOT | 3 | GE | 3 |
| ENDP | 3 | STJ | 3 |
| LDK | 3 | NEM | 3 |
Entities who have mentioned AGN
- Citi | View Related Stories »
- Trading Radar | View Related Stories »
- Carl Icahn | View Related Stories »
- UBS | View Related Stories »
- Dividend | View Related Stories »
- Deutsche Bank | View Related Stories »
- Goldman Sachs | View Related Stories »
- Morgan Stanley | View Related Stories »
- Piper Jaffray | View Related Stories »
- Jefferies & Co | View Related Stories »
- Credit Suisse | View Related Stories »
- Notable Analyst Rating Changes | View Related Stories »
- Cowen & Co | View Related Stories »
- S&P Equity Research | View Related Stories »
- Bear Stearns | View Related Stories »
- Longbow Research | View Related Stories »
- Brean Murray Carret & Co. | View Related Stories »
- Morningstar, Inc. | View Related Stories »
- Robert W Baird | View Related Stories »
- HSBC | View Related Stories »
- Needham & Company | View Related Stories »
- Vanguard | View Related Stories »
- Life, Style and Real Estate | View Related Stories »
- 13G | View Related Stories »
- Factory Orders | View Related Stories »
View All Major News StreetInsider.com Major News for AGN
- Allergan (AGN) Reports Inline Q4 Adj-EPS of $0.78; Guides Q1, FY10
- Allergan (AGN) Posts Q3 EPS of $1.13, Topping Street; Guides FY09
- Allergan (AGN) Tops Q2 Views; Guides Q3, FY09; Declares $0.05 Qtr. Dividend
View All ReportsStreetInsider.com Reports on AGN
- Allergan (AGN) March put volatility flat at 34
- Allergan (AGN) Shares Jump Higher as Cowen Issues Intraday Upgrade
- Allergan (AGN) Reports Inline Q4 Adj-EPS of $0.78; Guides Q1, FY10
- Trading Radar for 02/04: Bunge (BG), Spectra Energy (SE), MasterCard (MA), Con-Way (CNW), Hospira (HSP) Report
- Allergan (AGN) Receives FDA Approval of JUVEDERM(R) XC
View All Press ReleasesCompany Press Releases on AGN
- THE Aesthetic Academy Debuts in Beverly Hills
- Allergan Reports Fourth Quarter 2009 Operating Results
- Allergan, Inc. Announces FDA Approval of JUVEDERM(R) XC Dermal Filler Formulated with Lidocaine
- Allergan Announces Quarterly Conference Call
- Pieris Appoints a New CEO
StreetInsider Reports on AGN by Category
View All BlogsBlogs on AGN
- Cramer's Mad Money - Waste Management: Get Some Cash for Your Trash (2/4/10)
- Allergan, Inc. Q4 2009 Earnings Call Transcript
- Allergan Earnings In-Line, Outlook Disappoints
- Allergan: Receives FDA Approval for Juvederm
- How We Decide What Stocks to Buy
View All FilingsSEC Filings on AGN
- Form 4 ALLERGAN INC For: Feb 05 Filed by: INGRAM DOUGLAS S
- Form 8-K ALLERGAN INC For: Feb 01
- Form 8-K ALLERGAN INC For: Feb 04
- Form 4 ALLERGAN INC For: Feb 01 Filed by: INGRAM ROBERT ALEXANDER
- Form 4 ALLERGAN INC For: Feb 01 Filed by: GALLAGHER MICHAEL R
Comments on recent AGN articles
Comments on AGN
No comments are currently available.
on Jul 26, 2009
at 03:45 PM allergan With their cosmetic and new eye and urinary meds I see Allergan going to 72
Article: Citi Upgrades Allergan (AGN) to Buy